Page 17 - Valuating News Today

MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosisData presented during poster and oral sessions at the 63rd American

WASHINGTON (dpa-AFX) - Centene Corporation (CNC) reaffirmed its 2021 total revenues guidance in the range of $125.2 billion to $126.4 billion and adjusted earnings per share guidance in the range

- Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months

By Stephen Nakrosis Merck & Co. said Monday it would pause enrollment in Phase 3 clinical studies evaluating oral islatravir for pre-exposure prophylaxis in people at high risk of HIV-1... | December 7, 2021

WAKEFIELD, MA / ACCESSWIRE / December 7, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provides shareholders with perspectives on the

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE

BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 --... | November 29, 2021

Connect Biopharma Holdings Limited announced that it has completed full enrollment of the phase 2 clinical trial evaluating CBP-307 in adult patients with moderate-to-severe Ulcerative Colitis . This... | November 20, 2021

Multi-center trial is being conducted in collaboration with Roche and AIO Trial is designed to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple

~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype ~ ~